All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Why is TIM-3 a good target for treating patients with high-risk MDS?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Andrew M. Brunner, Massachusetts General Hospital, Boston, US. We asked, Why is TIM-3 a good target for treating patients with high-risk MDS?

Why is TIM3 a good target for treating patients with high-risk MDS?

Current treatments available for patients with high-risk MDS achieve low overall response rates. In this video, Brunner explains the rationale for targeting TIM-3 in acute myeloid leukemia/MDS.


Share: